Articles tagged with Fatty Liver Disease
A study published in Diabetes journal found epigenetic changes in the DPP4 gene are associated with fatty liver development in both mice and humans. These changes, detected at six weeks of age, lead to increased enzyme production and correlate with fat content in the liver.
Researchers found that PQQ reduced fat in livers and inflammation, protecting adult mice from fatty liver even after stopping supplementation. The antioxidant may work by impacting pathways critical to early onset of diseases associated with maternal obesity and high-fat diets.
A new study identifies malondialdehyde as a key player in hepatic inflammation and finds it can be neutralized by specific natural antibodies. The research provides a promising approach towards a potential therapy for non-alcoholic fatty liver disease.
Researchers have found a new pathway in the liver that opens the door to treat non-alcoholic fatty liver disease. The pathway involves activating a protein called TRPV4, which releases nitric oxide and blocks an enzyme contributing to the disease.
The new guidelines developed by the NASPGHAN recommend regular screening for NAFLD in all obese children between 9-11 years old using a simple liver enzyme test. Lifestyle changes such as improving diet and increasing physical activity are also recommended as first steps in treatment.
Research reveals a strong connection between fatty liver disease and cardiovascular disease, with individuals with fatty liver at higher risk of developing high blood pressure, type 2 diabetes, and cardiovascular diseases.
NAFLD affects 64 million individuals worldwide, with annual direct medical costs of $103 billion in the US and €35 billion in Europe. The economic burden is even higher when including societal and indirect costs.
Researchers at Columbia University Medical Center discovered that inactivating the TAZ protein in liver cells reverses fibrosis, a primary feature of nonalcoholic fatty liver disease. This finding has potential implications for treating nonalcoholic steatohepatitis, a serious condition that can lead to liver failure and cancer.
Researchers developed a novel method to quantify NAFLD progression to advanced fibrosis and cirrhosis. The technique combines multiple non-invasive measures, including heavy water labeling and MRI assessments, to predict individual clinical fibrotic disease progression.
Researchers at Cardiff University developed a method to predict non-alcoholic steatohepatitis (NASH) through blood analysis, offering an early warning for potentially life-saving medical intervention. NASH is the most extreme form of non-alcoholic fatty liver disease (NAFLD), with inflammation causing scarring and cirrhosis.
Researchers at the University of California San Diego have developed a non-invasive MRI technique that measures liver fat density with high accuracy. This method corresponds to histological responses in patients with nonalcoholic steatohepatitis and shows promise for future clinical trials and treatment.
Researchers at the University of Colorado Anschutz Medical Campus found that sleep apnea worsens non-alcoholic fatty liver disease in obese adolescents. The study, published in the Journal of Hepatology, suggests that obstructive sleep apnea and low nighttime oxygen levels can promote the progression of the disease.
Obstructive sleep apnea and low nighttime oxygen are linked to NAFLD progression in children. Researchers found a correlation between severity of sleep-disordered breathing and oxidative stress, which promotes the development of non-alcoholic steatohepatitis.
Chronic liver disease and cirrhosis show differing patterns among ethnic minorities in the US. Nonalcoholic fatty liver disease (NAFLD) is the most common cause of CLD and cirrhosis in Japanese Americans, Latinos, Native Hawaiians, and others.
Researchers have created a diagnostic model called the Framingham Steatosis Index (FSI) that can accurately predict nonalcoholic fatty liver disease (NAFLD). The FSI is highly predictive and may become a cheaper alternative to screen for liver fat.
Researchers found that moderate and vigorous exercise reduce intrahepatic triglyceride content, a key indicator of NAFLD, with no significant difference between the two. Exercise also leads to significant weight loss and reduced body fat mass in patients with obesity.
A study published in Cell Reports has found that inhibiting the enzyme cdk4 can prevent and reverse the initial stage of Non Alcoholic Fatty Liver Disease (NAFLD). Researchers at Cincinnati Children's Hospital Medical Center used two FDA-approved drugs to inhibit cdk4, significantly reducing hepatic steatosis in mouse models.
Researchers developed an in vitro model system for NAFLD using human pluripotent stem cell-derived immature hepatocyte-like cells. The study replicated key steps of the disease, including lipid storage and PPARalpha regulation.
In a 24-week study, aerobic exercise training improved cardiopulmonary functional capacity and reduced waist circumference in postmenopausal women with nonalcoholic fatty liver disease. Exercise also increased high-density lipoprotein cholesterol levels, but did not significantly affect body composition or glycemic profiles.
Researchers found that several commercially available tests for hepatitis C virus core antigen are highly sensitive and specific, potentially replacing the current two-test screening process with a single test. This could streamline care in low- and middle-income countries where HCV is prevalent, but patients are often lost to follow-up.
A 40-year study of nearly 45,000 Swedish men found that being overweight in late adolescence significantly increases the risk of developing severe liver disease later in life. The study adjusted for various confounding factors and found a 64% increased risk for overweight men compared to those with low normal weight.
Research reveals that people with low ALDH2 activity, common in East Asian populations, are more likely to develop non-alcoholic fatty liver disease (NAFLD). Even those who don't drink heavily or at all are at risk. Regular γ-GTP level checks are recommended.
A randomized clinical trial found that sitagliptin was not significantly better than a placebo in reducing liver fat in patients with NAFLD. However, advanced imaging techniques such as MRI-PDFF and magnetic resonance elastography proved to be accurate and useful in measuring disease state and progression.
A large retrospective study found that nonalcoholic fatty liver disease (NAFLD) independently contributes to increased atherosclerosis and cardiovascular mortality. Patients with fatty liver were more likely to develop carotid plaques over time, highlighting the need for thorough cardiovascular and metabolic work-ups in NAFLD patients.
A new study demonstrates that a build-up of fat around the waist can cause more serious complications than obesity in the development of non-alcoholic fatty liver disease (NAFLD). Non-obese patients with a large waist circumference are at risk of NAFLD complications, according to the research. The study highlights the need for addition...
A new study published at The International Liver Congress 2016 found that the diabetes drug sitagliptin was no more effective than placebo in reducing non-alcoholic fatty liver disease. However, researchers demonstrated that non-invasive imaging techniques based on MRI were useful for measuring changes in liver fat and fibrosis.
A new scoring system can accurately predict a person's risk of death from non-alcoholic fatty liver disease (NAFLD), the world's most prevalent liver disease. The study found that patients with severe NAFLD had a significantly higher risk of mortality, highlighting the importance of identifying patients at risk.
Research presented at The International Liver Congress 2016 found that breastfeeding exclusively for six months can reduce the risk of non-alcoholic fatty liver disease (NAFLD) in adolescence by a third. Pre-pregnancy BMI within the normal range also reduces the risk, by half.
A new study found that coffee supplementation improved several key markers of NAFLD in mice fed a high-fat diet, including reduced cholesterol and fat accumulation. Coffee also raised levels of Zonulin, which lessens gut permeability, a contributor to liver injury.
Research shows people with type 2 diabetes are more susceptible to non-alcoholic fatty liver disease (NAFLD), a condition characterized by a build-up of fat in liver cells. The study found that hospital admissions and deaths caused by liver disease are likely to rise if cases of type 2 diabetes continue to increase.
Researchers at Newcastle University have developed a DNA-based blood test that can detect liver scarring, also known as fibrosis, in patients with NAFLD. This breakthrough test measures epigenetic markers to stratify patients into mild or severe liver scarring, offering an early diagnosis and potentially improving patient outcomes.
Researchers developed a novel 3D imaging technique that provides accurate detection of advanced fibrosis in liver disease. The technology outperforms current methods, offering improved accuracy and reduced invasiveness.
A new study published in Radiology found that fatty liver disease is independently associated with subclinical heart failure in obese people. The study, which measured hepatic triglyceride content and cardiac function in 714 adults, suggests that dietary interventions may be crucial in preventing or reducing the risk of heart failure.
Researchers suggest GPR119 could treat nonalcoholic fatty liver disease, with administration of its ligand reducing hepatic lipid accumulation in mice. This discovery opens the door to developing new treatments for this increasingly prevalent disease.
Researchers have found a compound that can prevent and reverse fatty liver disease and obesity in mice by targeting the farnesoid X receptor. The compound, Gly-MCA, was tested in obese and diabetic mice fed with a high-fat diet and showed significantly less fat and insulin resistance compared to untreated control groups.
A new study found that obese children and those with Non-Alcoholic Fatty Liver Disease (NAFLD) are not meeting the UK's vitamin and mineral guidelines. They are also significantly off meeting the recommended physical activity levels, with excess weight unlikely to be the only factor in NAFLD development.
Researchers have found that a commonly used Type II diabetes medication can effectively clear fatty liver disease from some patients. After a 48-week trial, 4 out of 10 patients showed significant improvement in non-alcoholic steatohepatitis symptoms.
A genetic variant has been found to increase the risk of fatty liver disease in obese children and adolescents, despite lower total and LDL cholesterol levels. The variant affects the TM6SF2 protein, which regulates fat metabolism in the liver.
A large study of middle-aged Koreans reveals that both sedentary behavior and reduced physical activity contribute to the prevalence of NAFLD. The findings support increasing physical activity and reducing sitting time as crucial in reducing the risk of NAFLD.
Researchers found that normal-weight carriers of the PNPLA3 mutant genotype are at higher risk for non-alcoholic fatty liver disease (NAFLD) and renal function dysfunction. The study suggests this mutation may be used to identify individuals at high-risk for NAFLD, regardless of weight status.
A daily sugar-sweetened beverage habit may increase the risk for non-alcoholic fatty liver disease (NAFLD), researchers found in a study of over 2,600 adults. Consuming more than one sugar-sweetened beverage per day was associated with a higher prevalence of NAFLD.
A large population-based cohort study found that non-alcoholic steatohepatitis (NASH) increases the risk of death by 50% compared to non-alcoholic fatty liver disease (NAFLD). The study also showed that patients with NASH had a higher risk of cardiovascular disease and all-cause mortality over a 14-year period.
A new study published at The International Liver Congress reveals that non-alcoholic fatty liver disease (NAFLD) is associated with the development of coronary artery calcification. In patients without existing CAC, NAFLD significantly accelerated atherosclerosis progression, while in those with existing CAC, it did not affect disease ...
Remogliflozin etabonate improves insulin sensitivity and beta cell function, reducing ALT levels and weight in patients with NASH. The investigational drug also exhibits intrinsic anti-oxidant activity, reversing steatohepatitis and oxidative stress.
A study has demonstrated that alginate-enriched bread can inhibit fat digestion and circulatory lipids in patients with non-alcoholic fatty liver disease (NAFLD). The results show a significant reduction of up to 31% in fat digestion, suggesting its potential use as a therapeutic weight management therapy.
Recent studies confirm that NAFLD worsens heart disease and increases serum levels of cardiovascular risk markers. Additionally, a large population sample found a significant association between psychological distress and liver disease mortality. Meanwhile, inpatient mortality for cirrhosis patients has decreased by 41% in the U.S., at...
A new study published in the Journal of Hepatology shows that exercise, regardless of frequency or intensity, benefits obese and overweight adults with non-alcoholic fatty liver disease (NAFLD). Both aerobic and resistance training-based exercise regimens reduce liver fat and visceral fat. The improvement was independent of weight loss.
Research links non-alcoholic steatohepatitis (NASH) with increased intestinal permeability, suggesting a 'gut-liver axis' role in its development. The study found that liver injury may precede changes in gut permeability, potentially worsening liver disease.
A new oral, controlled-release form of DNP, known as CRMP, reversed fatty liver, insulin resistance, and hyperglycemia in rat models of NAFLD and type 2 diabetes, with no adverse effects. The therapy achieved plasma concentrations that were more than a 100-fold less than the toxic threshold.
Saint Louis University researchers have tested a promising drug candidate that stopped fatty liver disease from progressing to severe liver damage. The drug, SR9238, suppresses lipogenesis and reduces the liver's ability to produce fat.
Non-alcoholic fatty liver disease (NAFLD) affects 25% of adults in the US, with excessive fat building up in liver cells. Researchers at BMC will investigate molecular mechanisms and identify novel treatments for NAFLD using retinoic acid and its nuclear receptor.
Researchers at UC San Diego have developed an MRI-based technique to detect and evaluate nonalcoholic fatty liver disease (NAFLD) in children. The new method estimates liver fat content using a standardized biomarker, PDFF, which correlates well with standard liver biopsy analysis.
A team of researchers found that inhibiting the intestinal farnesoid X receptor with drugs like tempol and antibiotics can prevent nonalcoholic fatty liver disease in mice. This discovery highlights the complex role of gut microbes in human health and potential targets for treating metabolic disorders.
A new study links molecular signaling pathways in the gut, intestinal microbiome, and development of nonalcoholic fatty liver disease (NAFLD). Disruption of the gut microflora prevented NAFLD in mice fed a high-fat diet, suggesting that altering microbial populations may protect against the disease.
A recent study found that obese children with nonalcoholic fatty liver disease (NAFLD) are at a substantial risk for high blood pressure, which can lead to premature cardiovascular disease. The study recommends that blood pressure evaluation and control should be included in the clinical management of children with NAFLD.
Two new treatments for liver diseases are being explored. A probiotic, VSL#3, has been shown to improve liver function and reduce the risk of hospitalization in patients with cirrhosis. Meanwhile, a fatty acid conjugate called Aramchol has been found to significantly reduce liver fat content in patients with nonalcoholic fatty liver di...
Researchers used coronary computed tomography angiography (CCTA) to detect high-risk coronary artery plaque and non-alcoholic fatty liver disease (NAFLD), a condition characterized by abnormal liver function. The study found that NAFLD is associated with high-risk plaque, even after adjusting for traditional risk factors.
A study in mice reveals that dysfunctional ketogenesis promotes fatty liver disease, characterized by excessive hepatic glucose and lipid production. The findings suggest targeting ketogenesis could be a viable approach to treating NAFLD.
A team of scientists led by Prof. Mathias Heikenwälder found that immune cells, particularly CD8+ T cells and NK T cells, play a crucial role in the development of fatty liver disease, non-alcoholic steatohepatitis (NASH), and liver cancer. The study suggests that an existing metabolic imbalance triggers the activation and migration of...
A six-month treatment with tesamorelin lowered liver fat modestly but significantly in HIV patients. The drug's impact on glucose metabolism was temporary, and reduced liver inflammation may result from lower fat levels.